Pleconaril: Phase III

University of California School of Medicine (San Diego) researchers presented final data from a study of 221 children ages 4-14 showing 50, 38 and 46 percent reductions in headache, disease symptoms or global assessment score (GAS), respectively, after 8 days compared to placebo. The trial failed to show a significant reduction in the primary end point of time to headache (see BioCentury, Nov. 9, 1998). ...